Navigation Links
Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents

JAMA, February 27, 2008 - Vol. 299. No. 8: 'Venous Thromboembolism and

Mortality Associated with Recombinant Erythropoietin and Darbepoetin

Administration for the Treatment of Cancer-Associated Anemia'

BRIDGEWATER, N.J., Feb. 26 /PRNewswire/ -- Ortho Biotech believes that the conclusions of a study published in the February 27, 2008 issue of the Journal of the American Medical Association (JAMA) by Bennett, et al, do not provide an accurate reflection of the safety profile of erythropoiesis-stimulating agents (ESAs) when used for the treatment of chemotherapy-induced anemia (CIA) in patients with cancer.

The company reaffirms that, when used according to product labeling, ESAs remain safe and effective, and are the only proven treatment alternative to blood transfusions for patients with CIA.

Ortho Biotech also provides comment on the following important topics.


Ortho Biotech acknowledges that all meta-analyses have limitations. However, the JAMA authors recognize that a significant limitation of this analysis is that it does not analyze patient-level data from all available controlled studies with ESAs.

In a separate effort, Ortho Biotech, along with the other ESA manufacturers, has provided individual patient-level data to the independent Cochrane Collaboration to support a combined analysis of all available controlled studies with ESAs in oncology patients. This project will be the largest combined analysis of ESA safety data ever undertaken. It will create a database of more than 15,000 patients treated in various clinical studies, which should inform the benefit:risk profile of ESAs by identifying patient subgroups that would benefit from further study.


Vascular thrombotic events (VTEs) are a well-recognized risk of ESA treatment and are prominently reflected in the labeling for all ESAs. It is important to understand that VTEs are common in cancer patients. VTEs may

SOURCE Ortho Biotech
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
2. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
3. New Orthopedic Surgical Robotics Company Opens Its Doors; Files with the FDA for Clearance of Its Flagship Product
4. Innovative Neurotronics, a Subsidiary of Hanger Orthopedic Group, Earns the 2007 da Vinci Award for the WalkAide System
5. Bone-growing nanomaterial could improve orthopaedic implants
6. Advancements in Population Age and Technology Drive Future of Orthopedic Materials Market
7. Collagen Matrix, Inc. Launches OssiMend(TM) Bone Graft Matrix for Orthopedic and Spine Applications
8. Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) Label Reflects Recommendations from Recent FDA Advisory Committee Meetings
9. Progentix Orthobiology B.V. Closes Series A Financing Round
10. Barr and Ortho Womens Health & Urology in Discussions to Settle ORTHO TRI-CYCLEN(R) LO Patent Litigation
11. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
Post Your Comments:
(Date:4/16/2015)... (PRWEB) April 16, 2015 Capillus, ... distribution and physician network in Europe and Asia. ... has appointed Fernando Bermúdez, former Business Development Director ... An industry veteran, Mr. Bermúdez’s professional achievements include ... in Spain, while also penetrating the Portuguese marketplace ...
(Date:4/16/2015)... Morton Grove, IL (PRWEB) April 16, 2015 ... the American Association for Cancer Research (AACR) ... at the Pennsylvania Convention Center, starting Saturday, April 18, ... The AACR holds claim to title of the oldest ... several journals, provides fellowships and grants, and partners with ...
(Date:4/16/2015)... The Council for Agricultural Science ... Borlaug CAST Communication Award goes to Dr. Channapatna ... in Alabama. Award nominees must demonstrate an ability ... the use of television, radio, or other social ... a specialist in the field of plant genetics ...
(Date:4/16/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... with G-treeBNT (ReGenTree LLC) has retained Ora, Inc. ... the orphan disorder, neurotrophic keratopathy (NK), and a ... (DES) in the U.S.  Both trials will be ... Each of these eye disorders was being targeted ...
Breaking Biology Technology:Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2Regis Technologies Joins American Association for Cancer Research Annual Meeting 2The 2015 Borlaug CAST Communication Award Goes to Channapatna Prakash 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
... Assets, Talent, ANN ARBOR, Mich., Nov. 29 ... state of Michigan through the 21st Century,Jobs Fund. The ... loan,fund with a low interest rate, is intended to ... region. Job creation is vital for,consideration for approval of ...
... Nov. 29 As part of an ongoing ... maximize commercial,impact of their products, Premier Research Group ... industry-leading expertise in its core,service areas into a ... expertise within the group closely matches Premier Research,s ...
... Protalix,BioTherapeutics, Inc. (Amex: PLX ), today announced that ... on December 24, 2007, as the record,date for shareholders ... the,Company,s 2007 Annual Meeting of Shareholders. It is currently ... be held on,January 31, 2008, in Tel Aviv, Israel., ...
Cached Biology Technology:Ann Arbor SPARK Receives $3.75M from Michigan's Company Formation & Growth Fund 2Ann Arbor SPARK Receives $3.75M from Michigan's Company Formation & Growth Fund 3Product Development Timelines and Commercialization Strategy Are Focus of New Group at Premier Research 2Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders 2Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders 3
(Date:4/2/2015)... 2015 In the current ... outperforms the strongest competitors, showing outstanding performance in ... system is capable of a throughput of 5.000.000 ... to be ten times faster than most competitors ...      (Photo: ) ...
(Date:4/1/2015)...   Medisafe ™, the leading global medication management ... and Android smartphones and tablets, announces ... platform to allow patients to track and correlate their ... patients will be able to visualize in real-time how ... such as glucose levels and blood pressure. ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... coactivators control the process by which a single gene ... called alternative splicing, said Baylor College of Medicine researchers ... the journal Molecular Cell. "A major question in biology ... at least 120,000 proteins," said Dr. Bert O'Malley, chair ...
... Starvation, malnutrition and re-feeding can have deadly consequences for ... frog. , PhD student Rebecca Cramp from The University ... can't digest food after long periods of starvation, the ... percent more effectively after 3 months without food, than ...
... immunodeficiency virus (HIV), highly active antiretroviral therapy (HAART) ... and non-Hodgkin lymphoma, according to a new study ... of the National Cancer Institute. , Studies of ... increased risks of several cancers, including Kaposi sarcoma, ...
Cached Biology News:Controlling protein diversity 2A frog's life is food for thought 2A frog's life is food for thought 3Antiretroviral therapy may prevent excess risk of some cancers in people with HIV 2
... Solid phase reagent for ... Easy & unique water ... with detergents and chaotropes; ... recover non-envelop viruses while ...
Mouse monoclonal [Ley 37D/G6] to LKB1 ( Abpromise for all tested applications). entrezGeneID: 6794 SwissProtID: Q15831...
Non-Receptor Tyrosine Kinase Sampler Kit 10 mu g each...
Mouse monoclonal [3A7.A11] to Thymidylate Synthase ( Abpromise for all tested applications). entrezGeneID: 7298 SwissProtID: P04818...
Biology Products: